****Published September 2019***

MarketVIEW: Periodontal (*P. gingivalis*) vaccines (CAT: VAMV083)

Product Name	:	**MarketVIEW:** Periodontal (*P. gingivalis*) vaccines
Description	:	Global commercial opportunity assessment
Contents	:	Executive presentation (~100 slides.pdf) + 1 x MS-Excel forecast model (.xls)
Therapeutic Area	:	**Periodontal vaccines**
Publication date	:	September 2019
Catalogue No	:	VAMV083

Background

Periodontal disease or 'gum disease' is a hugely prevalent inflammatory condition in adults affecting around two-thirds of the world population (mild/moderate and severe disease). The disease has become a global health concern and exerts substantial economic burden on healthcare systems due to the cost of mechanical surgical, dental treatment.

The bacterium ***Porphyromonas gingivalis (P. gingivalis)*** has been identified as a 'keystone' dysbiotic pathogen in periodontitis which causes impaired immunity through its interaction with the host complement system. The bacterium has a high prevalence in periodontitis patients and an association with alveolar bone loss. Research studies have demonstrated that specific blocking of *P. gingivalis* can reverse dysbiotic effects and protect against periodontal disease indictors, thereby implicating this mechanism as a potential therapy. In addition to its involvement in periodontal diseases, *P. gingivalis* also has a demonstrated association with many other chronic diseases such as **cardiovascular**, **kidney**, **metabolic, respiratory disorders, cancer** and has even more recently been implicated in **Alzheimer's disease**. Evidence for its association and potential involvement in the pathogenesis of these additional chronic conditions is further strengthening a hypothesis for its selective targeting with a therapeutic.

This **MarketVIEW** product contains a comprehensive MS Excel-based model + Executive presentation that forecasts the potential commercial value of *P. gingivalis* vaccines across Western economies until 2040. The model contains value ($ m) and volume (million doses) predictions for an example vaccine-targeted segment along with timeframe, pricing and penetration estimates. The product also includes an in-depth review of periodontitis disease, epidemiology, treatments/guidelines and most recent developments in R&D (academic and commercial). It is an ideal "first pass" look at this intriguing vaccine opportunity.

Bringing life to vaccine strategy...   www.vaccine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaccine-analytics.com

Methodology

VacZine Analytics has used source materials, including literature articles, government websites, medical bodies and associations, conference proceedings etc which cover *P.gingivalis* and periodontal disease.

PRODUCT CONTENTS:

Published September 2019 (CAT No: VAMV086)

****This product is a summary presentation (.pdf), a forecast model (.xls)

Contents – Summary presentation (.pdf)[1]

Contents
Author's notes
Executive summary
[SECTION 1] *P. gingivalis* vaccines: key commercial model outputs
[SECTION 2] Periodontal diseases: disease background and treatments
[SECTION 3] Periodontal diseases epidemiology
[SECTION 4] Periodontitis: *P. gingivalis* and the pathogenesis of disease
[SECTION 5] *P. gingivalis* and the association with chronic diseases
[SECTION 6] *P. gingivalis* vaccines: research, development and current progress
[SECTION 7] *P. gingivalis* vaccines: modelling commercial potential
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~100 slides fully referenced/sourced. Available in .pdf form

Contents – Vaccine model (MS Excel-based)

Worksheets = >20 interconnected sheets

BIBLIOGRAPHY

~250 References – only available upon a valid request

---

[1] Full contents i.e. title per slide is proprietary and only available upon valid request

Bringing life to vaccine strategy...

www.vaccine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaccine-analytics.com

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o FULL PRODUCT (both deliverables) - USD **$7,995.00**/ GBP **£6,600.00**# (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to the final invoice total
 # - indicative prevailing rate will be applied on date of transaction, third-party licenses may be restricted/vary

HOW TO ORDER:
To order, please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.

VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics ® and the **"spiral logo"** are UK Registered Trademarks, 2009

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as "The Company"). (Herein [enter client name] to as "The Client").

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (a division of Assay Advantage Ltd).

2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.

3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.

4. If not purchased online invoices are payable within **thirty days** of the invoice date.

5. All proposals are quoted in **$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.

6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees, and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics
A division of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049 / Fax: +44 (0) 1279 927049
E-mail: info@vacZine-analytics.com

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new monoclonals and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics ® and "the spiral logo" are UK Registered Trademarks, 2009

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   Tel. +44(0)1279 927049   e-mail: info@vaczine-analytics.com